Aclaris Therapeutics (ACRS) Research & Development: 2017-2025
Historic Research & Development for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $13.0 million.
- Aclaris Therapeutics' Research & Development rose 118.74% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.1 million, marking a year-over-year decrease of 11.95%. This contributed to the annual value of $33.6 million for FY2024, which is 65.86% down from last year.
- As of Q3 2025, Aclaris Therapeutics' Research & Development stood at $13.0 million, which was up 13.79% from $11.4 million recorded in Q2 2025.
- Aclaris Therapeutics' 5-year Research & Development high stood at $26.6 million for Q4 2023, and its period low was $6.0 million during Q3 2024.
- Over the past 3 years, Aclaris Therapeutics' median Research & Development value was $11.6 million (recorded in 2025), while the average stood at $15.3 million.
- As far as peak fluctuations go, Aclaris Therapeutics' Research & Development skyrocketed by 137.80% in 2022, and later plummeted by 75.05% in 2024.
- Quarterly analysis of 5 years shows Aclaris Therapeutics' Research & Development stood at $14.1 million in 2021, then surged by 49.43% to $21.1 million in 2022, then rose by 26.45% to $26.6 million in 2023, then tumbled by 66.13% to $9.0 million in 2024, then spiked by 118.74% to $13.0 million in 2025.
- Its Research & Development stands at $13.0 million for Q3 2025, versus $11.4 million for Q2 2025 and $11.6 million for Q1 2025.